Table S1. Univariate and multivariate analysis of factors potentially associated with PFS for subset receiving RT without concurrent chemotherapy.
| Characteristics | Univariate | Multivariate (NLR) (n=129) | Multivariate (PLR) (n=129) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |||
| Age | 1.006 | 0.985–1.028 | 0.560 | NI | NI | ||||||
| Male vs. female | 0.776 | 0.431–1.397 | 0.399 | NI | NI | ||||||
| Performance status | 0.699 | 0.310–1.578 | 0.389 | NI | NI | ||||||
| CCI ≥4 | 0.681 | 0.298–1.558 | 0.363 | NI | |||||||
| Smoking index | NI | NI | |||||||||
| <200 | Ref | ||||||||||
| ≥200 | 0.838 | 0.567–1.237 | 0.373 | ||||||||
| Weight loss ≥5% | 0.420 | 0.103–1.707 | 0.225 | NI | NI | ||||||
| Histology | NI | NI | |||||||||
| Squamous | Ref | ||||||||||
| Adenocarcinoma | 0.703 | 0.457–1.082 | 0.109 | ||||||||
| NOS | 0.778 | 0.384–1.573 | 0.484 | ||||||||
| T stage | 1.026 | 0.862–1.225 | 0.770 | NI | NI | ||||||
| N stage | 1.051 | 0.766–1.444 | 0.756 | NI | NI | ||||||
| GTV (cc) | 1.002 | 1.001–1.004 | 0.001 | 1.002 | 1.000–1.003 | 0.040 | – | – | 0.101 | ||
| Prescribed dose (Gy) | NI | NI | |||||||||
| <60 | Ref | ||||||||||
| ≥60 | 0.830 | 0.518–1.331 | 0.440 | ||||||||
| Number of chemo | 0.971 | 0.907–1.040 | 0.403 | ||||||||
| Baseline ALC | 0.818 | 0.598–1.118 | 0.207 | NI | NI | ||||||
| 1-month ALC | 0.474 | 0.253–0.888 | 0.020 | – | – | 0.756 | – | – | 0.790 | ||
| 1-month post-RT ALC | 0.549 | 0.301–1.000 | 0.050 | NI | NI | ||||||
| ALCmin | 0.387 | 0.186–0.805 | 0.011 | – | – | 0.505 | – | – | 0.432 | ||
| Baseline NLR | 1.029 | 0.953–1.112 | 0.465 | NI | NI | ||||||
| 1-month NLR | 1.068 | 1.031–1.106 | <0.001 | 1.054 | 1.014–1.096 | 0.008 | NI | ||||
| 1-month post-RT NLR | 1.000 | 0.954–1.049 | 0.986 | NI | NI | ||||||
| Baseline PLR | 1.001 | 0.999–1.003 | 0.388 | NI | NI | ||||||
| 1-month PLR | 1.002 | 1.001–1.002 | <0.001 | NI | 1.002 | 1.001–1.002 | <0.001 | ||||
| 1-month post-RT PLR | 1.002 | 1.000–1.003 | 0.073 | NI | NI | ||||||
| Mean heart dose | 1.000 | 1.000–1.000 | 0.027 | – | – | 0.071 | 1.000 | 1.000–1.000 | 0.044 | ||
| Heart V5 (%) | 1.006 | 1.000–1.012 | 0.046 | – | – | 0.092 | – | – | 0.809 | ||
| Heart V20 (%) | 1.009 | 1.001–1.018 | 0.034 | – | – | 0.091 | – | – | 0.651 | ||
| Heart V40 (%) | 1.012 | 0.999–1.026 | 0.065 | NI | NI | ||||||
| Mean lung dose | 1.001 | 1.000–1.002 | 0.058 | NI | NI | ||||||
| Lung V5 (%) | 1.020 | 0.999–1.042 | 0.063 | NI | NI | ||||||
| Lung V20 (%) | 1.041 | 1.001–1.082 | 0.042 | – | – | 0.270 | – | – | 0.283 | ||
| Mean body dose | 1.001 | 1.000–1.003 | 0.004 | – | – | 0.503 | – | – | 0.309 | ||
PFS, progression-free survival; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; β, standardized coefficient; CI, confidence interval; NI, not included in the multivariate model; CCI, Charlson Comorbidity Index; GTV, gross tumor volume; ALC, absolute lymphocyte count; VX, the proportion of volume receiving at least X Gy.